Passive immunotherapies targeting amyloid beta and tau oligomers in Alzheimer's disease.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of pharmaceutical sciences"
DOI: 10.1016/j.xphs.2019.10.024
Abstract: Alzheimer's disease (AD) is historically difficult to treat, in part due the inaccessible nature of brain pathology. Amyloid-β (Aβ) and tau proteins drive pathology by forming toxic oligomers that eventually deposit as insoluble amyloid plaques… read more here.
Keywords: alzheimer disease; passive immunotherapies; tau oligomers; pathology ... See more keywords